amount of a ricinoleate vehicle so as to prepare a formulation of
at least 45 mgml-1 of fulvestrant.
with dependent claims 20 to 22 to remain unchanged and claims
23. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration, wherein the pharmaceutical formulation comprises
fulvestrant, 15-25% weight of a pharmaceutically-acceptable
alcohol per volume of formulation, 10-25% weight of benzylbenzoate in a ricinoleate vehicle per volume of formulation